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Abstract
Identifying relevant signatures for clinical patient outcome is a fundamental task in high-throughput studies. Signatures,
composed of features such as mRNAs, miRNAs, SNPs or other molecular variables, are often non-overlapping, even though
they have been identified from similar experiments considering samples with the same type of disease. The lack of a
consensus is mostly due to the fact that sample sizes are far smaller than the numbers of candidate features to be
considered, and therefore signature selection suffers from large variation. We propose a robust signature selection method
that enhances the selection stability of penalized regression algorithms for predicting survival risk. Our method is based on
an aggregation of multiple, possibly unstable, signatures obtained with the preconditioned lasso algorithm applied to
random (internal) subsamples of a given cohort data, where the aggregated signature is shrunken by a simple thresholding
strategy. The resulting method, RS-PL, is conceptually simple and easy to apply, relying on parameters automatically tuned
by cross validation. Robust signature selection using RS-PL operates within an (external) subsampling framework to
estimate the selection probabilities of features in multiple trials of RS-PL. These probabilities are used for identifying reliable
features to be included in a signature. Our method was evaluated on microarray data sets from neuroblastoma, lung
adenocarcinoma, and breast cancer patients, extracting robust and relevant signatures for predicting survival risk.
Signatures obtained by our method achieved high prediction performance and robustness, consistently over the three data
sets. Genes with high selection probability in our robust signatures have been reported as cancer-relevant. The ordering of
predictor coefficients associated with signatures was well-preserved across multiple trials of RS-PL, demonstrating the
capability of our method for identifying a transferable consensus signature. The software is available as an R package rsig at
CRAN (http://cran.r-project.org).
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Introduction
Identification of relevant features from large data sets has been a
focus of many research fields for a long time. With the onset of
high-throughput genomic profiling technologies, robustness is
being perceived as an important factor in feature selection [1,2].
Generally speaking, a feature is robust if it is chosen by a method
invariably of cohort composition, assuming that all samples come
from the same population distribution. If an algorithm identifies
many of these robust features, then the algorithm can be
considered as robust as well. Robustness is a critical factor
especially in clinical studies, when the purpose is either to identify
the key players in the underlying biological systems, or to develop
clinically useful tests.
Unfortunately clinical studies are usually performed without an
explicit consideration of robustness in their experimental design. A
typical example is to perform feature selection on a single partition
of available cohort data, then to determine the success of selection
using the rest of data (often called as a test set). When sample sizes
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are small as in most clinical studies, such practices can lead to
identifying diverse signatures from multiple studies that look
perfectly fine on their own evaluation but are not successful when
they are applied to the data from other studies.
In this paper we propose an algorithm to deal with the
aforementioned issues, based on well-studied ideas of subsampling
[3] and aggregation [4]. Our framework consists of two
subsampling steps: (i) an outer subsampling step, which estimates
the prediction performance of models and the selection probability
of features, and (ii) an inner subsampling step, which obtains a
robust model by aggregating many, possibly unstable, models,
where each model is obtained from a subsample.
In the outer subsampling, we essentially perform bootstrapping
[3] to estimate two quantities: the selection probabilities of features
and the prediction performance of models composed of robust
signatures. The estimation of selection probabilities of features
using subsamples has also been used in Davis et al. [1], in the
context of choosing the best combination of a feature selection and
a separate classification algorithm to maximize both selection
frequency of features and classification accuracy. In our method,
feature selection and model fitting are performed simultaneously,
and it is an intrinsic property that relevant features are to be
chosen with high probability. Therefore we use estimated selection
probabilities for constructing robust signatures, not for finding the
best combination.
The use of aggregation to produce robust signatures as in our
inner subsampling step has been used in different contexts. Abeel
et al. [5] considered simple and weighted averages of decision
vectors from the support vector machines (SVMs) [6] and the
recursive feature elimination using SVMs [7], where each decision
vector is obtained from a bootstrap sample. In Broom, Do and
Subramanian [8], a modified framework has been proposed for
leaning structures in Bayesian networks. These works however do
not address the problem of identifying robust signatures from
censored survival outcome, a typical type of responses in clinical
research. Also, methods such as SVMs have no such guarantee
that important features will be selected with high probability over
different subsamples.
Our robust selection is based on theoretical arguments
developed recently for the widely used lasso algorithm [9] and
an extension called the preconditioned lasso algorithm [10], that
are introduced in the following section.
Cox Regression with the Lasso Penalty
Let us consider a cohort sample that consists of n patients,
where each of i~1,2, . . . ,n patients is profiled by a p-dimensional
feature vector xi and a survival annotation yi~(ti,ei): ti is the
length of survival in time and ei is an indicator for a clinical event
such that ei = 1 if an event has happened, and ei = 0 otherwise.
In the Cox regression [11], the risk for a patient having an event
at time t is modeled by a function hb(tDx)~h0(t) exp (bTx), where
h0(t) is the baseline hazard function, the exponentiation part
describes the effect of covariates, and bTx~b1x1z   zbpxp. An
estimate b^ of the coefficient vector b is obtained by the maximum
likelihood estimation, that is,
b^[ argmin
b[Rp
{‘(b)zY(b), ð1Þ
where ‘(b) is the partial log-likelihood defined by
‘(b) :~log P
i[E
hb(tDxi)P
j[Ri
hb(tDxj)
 !
:
Here E is an index set enumerating all events and
Ri~fj : tj§tig is an index set of patients at risk with respect to
the time of an event i. The second term in Eq. (1) is a regularizer
penalizing the complexity of b,
Y(b) :~l aEbE1z(1{a)
1
2
EbE22
 
with lw0 and a[½0,1. We often call the regularization with a= 1
as the lasso or ‘1, and the one with a= 0 as the ridge or ‘2 penalty.
Lasso selects features by setting the coefficients in b to exactly zero
for irrelevant features, whereas the ridge does not perform feature
selection by itself. For the detailed comparison of the two, we refer
to Gui and Li [12]. For 0,a,1, the regularizer is called the elastic
net [13], which tends to select all correlated covariates together.
Preconditioned Lasso
The preconditioned lasso algorithm [10] is a two-step procedure
designed to address the problems of high bias in lasso estimates
when the number of features p is very large compared to the
number of patients n. The two steps are
1. Preconditioning step: f(xi,yi)gni~1?fy^igni~1.
2. Lasso step: fit a model to f(xi,y^i)gni~1.
The first step creates preconditioned outcomes y^i from the given
features and survival data. The preconditioning is performed by
the supervised principal components method [14], which first
ranks features fxig by their individual correlation to survival
outcomes fyig, and then find a threshold by cross validation that
gives the best prediction performance if the features ranked higher
than the threshold are used in regression after being projected onto
the first few principal components. The preconditioned outcomes
y^i are produced as the result of prediction on each feature vector
xi in a training set. Here y^i is real-valued, whereas the original
outcome yi~(ti,ei) contains a value of survival time and an event
indicator.
The second step uses lasso to fit a linear model to the original
feature vectors and the preconditioned outcome. Since precondi-
tioned responses y^i are scalars, we can use the ordinary least
squares regression with the lasso penalty,
b^’[ argmin
b[Rp
1
n
Xn
i~1
Ey^i{bTxiE22zlEbE1: ð2Þ
This problem can be solved efficiently with the least angle
regression (LARS) algorithm [15]. After a solution b^’ is found, a
linear risk prediction (b^’)Tx can be computed for each test
instance x and compared to their survival risk in forms of the Cox
model.
Consistency and Robust Signature Selection
Suppose that we obtain b^n by solving Eq. (1) with n examples,
where the examples are generated with an unknown population
parameter b under the Cox model. An important notion in
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statistics regarding robust feature selection is the consistency in
terms of variable selection,
P(fk : b^nk=0g~fk : bk=0g)?1, as n??: ð3Þ
That is, b^n selects the same features to b with increasing
probability as the number of patients increases. This implies that if
n is large enough or the convergence in Eq. (3) is fast enough for a
fixed n, then the feature subsets chosen by several b^n using
different samples of size n will be the same with high probability,
since all of them will be close to the features to be chosen by b.
Therefore for robust selection in clinical studies where the number
of patients n is relatively small and not easy to increase, we prefer
to using a method with fast convergence in consistency.
Recently it has been shown that under the irrepresentable
conditions [16] or equivalently the neighborhood stability conditions
[17], consistent estimates can be obtained by lasso, although these
conditions usually break in real situations. The preconditioned
lasso algorithm [10] is an alternative to lasso, producing consistent
estimates e.g. when p&n. For ordinary least squares with the lasso
penalty, it is shown that when the regularization parameter l is
chosen to be O(n{1=2), then each active element of b is chosen by
b^n with strictly positive probability [18]. Therefore an intersection
of feature sets obtained from bootstrap trials will be nonempty,
and be consistent with exponentially increasing probability as n
grows. However, the arguments are based on strong assumptions
that are rather easily violated in practice, and therefore the desired
property may not follow. Another modification of lasso has been
suggested using random reweighting of the lasso regularizer [19].
This algorithm produces consistent estimates in less restrictive
conditions than the previous approach, but requires to specify an
extra ‘‘weakness’’ parameter which is not straightforward to
determine in its randomized setting.
Our robust selection method is based on the following three
critical observations. First, preconditioned lasso has better
convergence in consistency than lasso when p&n [10]. Second,
variation in models can be reduced by model averaging combined
with subsampling [4] (inner subsampling step). And third, relevant
features are to be selected with positive probability with lasso
under certain conditions [18], and therefore will appear more
often than irrelevant features in multiple trials with random
subsamples (outer subsampling step).
A robust signature is defined as follows: given a random
subsample index set I5f1, . . . ,ng and an estimate b^I obtained
with examples corresponding to I, the robustness of a feature
indexed by k is defined as its probability of being selected amongst
all trials with random subsamples,
P(k) :~P(b^Ik=0),
where all parameters, if any, are assumed to be adjusted for each I.
A robust signature is defined as a set of robust features, whose
selection probabilities are above a certain threshold p[½0,1, that
is,
Sp :~fk[f1, . . . ,pg : P(k)§pg:
The above two definitions are adapted from Meinshausen and
Bu¨hlmann [19]. After evaluating selection probability of features
P^(k) in outer subsampling, we use it to identify an estimated
robust signature S^p,
S^p :~fk[f1, . . . ,pg : P^(k)§pg: ð4Þ
Methods
The workflow of our newly developed method is sketched in
Figure 1. The left panel (A) shows RS-PL, our Robust Selection
procedure with the Preconditioned Lasso algorithm, which
produces a coefficient vector b^I for each random train index set
I. In the right panel (B), we estimate the selection probability of
each feature chosen by the RS-PL algorithm for each random
train set I, testing the performance of predictors as well.
Our method RS-PL is designed to enhance the robustness of
lasso-based signature selection methods, in particular the precon-
ditioned lasso (PL). PL and RS-PL perform both signature
selection and estimation of a prediction function at the same time
in a tightly coupled manner. Therefore, improving robustness in
signature selection tends to improve prediction performance.
More specifically, predictors of RS-PL are based on an ensemble
of linear models of chosen features, and therefore robustness in
signature selection is directly connected to the stability of ensemble
models and their prediction outcome.
Robust Selection with Preconditioned Lasso (RS-PL)
Our suggested algorithm RS-PL in Figure 1 (A) corresponds to
an inner subsampling step in the entire framework, where a train
index set I is split into a sub-train set J (63.2%) and a tuning set
(the rest). These ratios are chosen to resemble the effective number
of samples in bootstrapping [3]. In comparison to other
subsampling strategies such as k-fold cross validation, this
particular way of subsampling is known to provide the best
estimation when noise in data is moderate [20].
Prefiltering. In RS-PL, we first remove uninformative
features from each train set (I) whose standard deviation values
are below a predefined percentile of the standard deviation values
of all features. This filtering is optional but facilitates feature
selection. In particular, a desirable number of candidate features p
can be determined using Lemma 6.7 [21], which states that the
number of features n to be chosen with statistical consistency with
the lasso and the preconditioned lasso is bounded by
nƒ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n=(log p)
p
for a sample of size n. In other words, p should
be no larger than exp(n=n2). For instance, p could be up to a few
thousands when n= 176 and n~5. In our experiments we
expected that n would be 5,10 and reduced the number of
candidate features as suggested by the lemma using prefiltering.
Preconditioned Lasso. At the core of RS-PL, we use the
preconditioned lasso algorithm (abbreviated as PL) discussed
above, because of its superior characteristics for the cases with
p&n. PL inside of RS-PL can be replaced by other algorithms as
long as they produce coefficient vectors for linear models, such as
the Cox regression with the lasso penalty.
Aggregation and Shrinking of Signatures. For each sub-
train set J5I , we obtain an estimate coefficient vector b^J as a
result of solving the second step of preconditioned lasso in Eq. (2).
For Tin = 100 random sub-train sets, say J1,J2, . . . ,JTin , we obtain
estimated coefficient vectors b^J1 ,b^J2 , . . . ,b^JTin respectively. Since
the coefficient vectors are from linear models, we can aggregate
them by a simple averaging, that is,
Robust Selection of Cancer Survival Signatures
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b^Ifull~
1
Tin
XTin
i~1
b^Ji , fb^Ifull=0g~
[
i~1,...,Tin
fb^Ji=0g:
Here the aggregated coefficient vector b^Ifull is denoted with the
letter I, since it is produced for each train set I in effect.
The number of features to be selected by the aggregated vector
b^Ifull tends to be quite large, since the set of nonzero components in
b^Ifull is the same as the union of signatures obtained with
b^J1 ,b^J2 , . . . ,b^JTin , as indicated above. Therefore we ‘‘shrink’’ the
coefficients in b^Ifull using a simple thresholding strategy: for
threshold values t1ƒt2ƒ . . .ƒt20 where t1 and t20 are the
smallest and the largest magnitude of components in b^Ifull, we find
a threshold t such that the shrunken signature fk : D½b^Ifullk D§tg
and its corresponding coefficients produce the best prediction
results over tuning sets, where tuning sets come from the inner
subsampling in Figure 1 (A). We denote the aggregated and
shrunken robust coefficient vector, the final outcome of RS-PL, as
b^I , constructed as follows:
½b^I k~
½b^Ifullk
0
if D½b^Ifullk D§t
otherwise
(
, k~1,2, . . . ,p: ð5Þ
Estimation of Selection Probability, Prediction
Performance, and Robustness
The algorithm in Figure 1 (B) corresponds to an outer
subsampling step, where the entire cohort data with n patients
are split into a train set I (63.2%) and a test set (the rest), randomly
for Tout = 100 times.
Preprocessing. There are two separate preprocessing steps
for each train set (I) and each test set. This separation is quite
important for accurate estimation of prediction performance. For
example, when we apply summarization and normalization
algorithms such as the robust multi-array analysis (RMA) [22] to
microarray data, we need to apply RMA separately on a train set
and a test set, since otherwise RMA will use information from a
test set to preprocess a train set, and vice versa, and therefore such
practice can yield overly optimistic prediction accuracy estima-
tions on the test set.
Alternatively, the frozen RMA (fRMA) algorithm [23] can be
applied independently to individual microarrays, using global
reference microarrays for normalization. Due to independence,
fRMA needs to be applied only once for all arrays regardless of
train/test splits.
Prediction of Risk. For prediction, a robust and shrunken
coefficient estimate b^I in Eq. (5) obtained by RS-PL is used to
compare the risk of patients having an event at time t, in terms of
the Cox proportional hazard model [11]. In this model, the log
hazard ratio comparing the risk of two patients (with profiles xi
and xj ) becomes
fxi : xj log hazard ratiog~log
hb^I (tDx
i)
h
b^I
(tDxj)
 !
~(b^I )T (xi{xj),
from the definition of the hazard (risk) function
hb(tDx)~h0(t)exp(bTx). The hazard ratio provides a statistic for
testing differences in survival patterns. It is worthwhile to note that
the baseline hazard h0(t) is cancelled out and does not play any role
in the above expression, making comparison of risk as simple as
comparing the values of linear predictors (b^I )Txi and (b^I )Txj .
This enables us to use a rank correlation between linear predictors
and survival times to assess prediction performance, as we discuss
in the next section.
Figure 1. An overview of the suggested framework. Panel A: our core algorithm (abbreviated as RS-PL) performs robust selection with an inner
subsampling, using the preconditioned lasso (PL) method inside. Potentially unstable model coefficient vectors b^J1 , . . . ,b^JTin are aggregated and then
shrunken to produce a robust model vector b^I . Panel B: an outer subsampling is used to evaluate the prediction performance of RS-PL and to
estimate selection probabilities of features. The ratios (63.2%:36.8%) are chosen to resemble the effective sampling ratios in bootstrapping.
doi:10.1371/journal.pone.0108818.g001
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On the other hand, the baseline hazard h0(t) can be estimated in
order to produce survival probabilities for individual patients. An
estimate of h0(t) is suggested by Cox and Oakes [24],
h^0(t
i)~
diP
j:tj§ti exp ((b^
I )Txj)
,
where t1,t2, . . . are the distinct event times and di is the number of
events at ti. Then the survival function (the probability to survive
at least to time t) for a patient x can be computed by,
S^x(t)~exp {
X
j:tjƒt
h^0(t
j)
0
@
1
A
exp((b^I )T x)
:
Measures for Prediction Performance. To measure pre-
diction performance, we use the concordance index [25], which is
the fraction of all comparable patient pairs whose outcomes are
concordant to predictions. A pair of patients is considered to be
usable except for the cases where both patients have events at the
same time, or one has shorter censored survival time than the
other who has an event. To explain formally, suppose that a
prediction pi~(b^I )Txi is available for each patient i~1,2, . . . ,n
whose survival time is given by yi~(ti,ei) with an event indicator
ei. Consider the following order indicator functions [26] for
i,j~1,2, . . . ,n,
orderP(p
i,pj)~
1 if piwpj
{1 if pivpj
0 otherwise,
8><
>:
orderT (t
i,ei,tj ,ej)
~
1 if tiwtj and ej~1 (tj is not censored)
{1 if tivtj and ei~1 (ti is not censored)
0 otherwise:
8><
>:
Then the product of the two order functions measures if the
order of a pair of predictions is concordant (product = 1),
disconcordant (21), or not comparable (0) to the order of the
corresponding survival time pair. The concordance index is
defined as the fraction of concordant pairs among all comparable
pairs,
fConcordance indexg
~
P
ivj x(orderP(p
i,pj)orderT (t
i,ei,tj ,ej)~1)P
ivj DorderT (ti,ei,tj ,ej)D
,
which has a value between 0 and 1. Here x(:) is an indicator
function returning 1 if the argument is true, and 0 otherwise. Note
that the numerator above counts the number of all concordant
pairs, where the denominator counts the number of all compa-
rable pairs (concordant or disconcordant). This measure can be
described as a generalized AUC (area under the ROC curve)
value, where values.0.5 imply positive correlation and values ,
0.5 imply negative correlation. For binary valued predictions, the
concordance index becomes identical to the AUC.
Measures for Robustness. In order to measure robustness
of signature selection, we use the Jaccard index and the rank-
penalized Kuncheva index.
The Jaccard index measures the robustness of signatures of
possibly different sizes, and it is defined as an average size of
overlap between feature subsets relative to the size of their union
[2]. Denoting the set of features chosen with b^Ii by
FIi :~fk : b^Iik=0g, it is defined as:
fJaccard indexg~ 2
Tout(Tout{1)
X
1ƒivjƒTout
DFIi\FIj D
DFIi|FIj D
: ð6Þ
The Jaccard index ranges from 0 to 1, and larger values indicate
larger relative overlap.
When the sizes of signatures can be controlled, more precise
measures of robustness are available, namely the Kuncheva index
[27] and the Canberra distance [28], instead of the Jaccard index
which can result in a biased evaluation of robustness. Specifically,
the Kuncheva index provides an unbiased estimate of average
overlap between signatures, and the Canberra distance measures
how well the order of contribution of features is preserved between
signatures on average. Compared to the Jaccard index, these two
measures require signatures to be of the same size for comparison.
The fraction between the Kuncheva index and the Canberra
distance, denoted as the rank-penalized Kuncheva index, is
computed as a summary of the two measures of robustness.
Denoting the G features chosen from b^I in an extra shrinkage by
FIG, and the rank in magnitude of the ‘th feature in F
I
G by r
I
‘ , the
rank-penalized Kuncheva index is expressed as follows (p is the
total number of candidate features),
Table 1. Three data sets for evaluation.
Data Set Source Platform n
Neuroblastoma GSE21713, GSE32664, and R2* Human Exon ST v1.0 176
Adenocarcinoma GSE31210 HG-U133 Plus 2 204
Breast Cancer GSE1456, GSE7390, GSE11121 HG-U133A 362
*R2: microarray analysis and visualization platform (http://r2.amc.nl).
doi:10.1371/journal.pone.0108818.t001
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Rank{Penalized
Kuncheva Index
( )
~
X
1ƒivjƒTout
DFIiG\F
Ij
G Dp{G
2
G(p{G)
0
@
1
A, X
1ƒivjƒTout
X
1ƒ‘ƒG
DrIi{rIj D
r
Ii
‘ zr
Ij
‘
0
@
1
A:
ð7Þ
The values of this index range from 0 (zero overlap, i.e., feature
ranks not preserved) to ‘ (perfect overlap, i.e., perfect preservation
of feature ranks).
Extra Shrinkage of Models. The number of features in a
signature described by b^I varies depending on data and methods,
but it is typically larger than 50. When smaller signatures are
preferred for an in-depth investigation of features, signatures
described by b^I can be shrunken further by choosing the top G
features according to the magnitude of their coefficient in b^I .
This is subsequently used for an evaluation of our method to
compare robustness and prediction performance of signatures
consisting of small numbers of features.
Selection Probabilities of Features and Robust
Signatures. The selection probability of a feature, indexed by
k, is estimated by its appearance frequency among the Tout outer
subsampling trials, that is,
P^(k)~
1
Tout
X
j~1,...,Tout
x(D½b^Ij kDw0), k~1,2, . . . ,p,
where x(s) is an indicator function which equals to 1 if the
statement s is true, or 0 otherwise. Given these probabilities and a
baseline selection probability p, we construct a robust signature
according to Eq. (4).
List of Algorithms for Comparison
Our suggested algorithm RS-PL, where the prefix ‘‘RS’’ stands
for ‘‘robust selection’’, is compared to the following algorithms.
RS-L is the same as RS-PL, except that PL inside of RS-PL is
replaced with the Cox regression with the lasso penalty. In the
following, the entire RS-PL in Figure 1 (A) is replaced with the
described algorithms, that do not make use of our RS framework:
PL is the preconditioned lasso algorithm. L is the Cox regression
with the lasso penalty. Dev is a simple method that selects the top
100 features with the largest standard deviation across micro-
arrays. A ridge Cox regression is then performed, using only these
features. This type of methods is known to be stable [29]. Cor is
another univariate method, choosing the top 100 features with the
highest ranks in terms of their individual correlation to survival
annotation (measured by the concordance index). A ridge Cox
regression is performed on the selected features afterwards. Cli is a
Cox regression without penalty using only clinical covariates. The
BatchExperiments package [30] for R was used for parallel
computation of algorithms.
Results
Data Preparation
Three data sets were analyzed containing mRNA expression
profiles from a total of 742 cancer patients that were acquired by
using Affymetrix microarray technology. Data were obtained for
three different entities, neuroblastoma, lung adenocarcinoma, and
breast cancer, as summarized in Table 1. CEL files were
downloaded from the Gene Expression Omnibus or the R2
platform (http://r2.amc.nl). For preprocessing, the frozen RMA
algorithm [23] was applied to individual CEL files to create
probeset level summaries. Only microarrays with the median
GNUSE [31] values #1 (for quality control) and with appropriate
clinical information (overall survival) were included in this study.
The characteristics of three data sets before and after preprocess-
ing are summarized in Tables 2, 3, and 4 (see Figure S1 for the
corresponding Kaplan-Meier plots).
Table 2. Characteristic of patients before/after GNUSE filtering (neuroblastoma).
Categories Groups Before (n=295) After (n=176)
Age (yrs) #1:.1:NA 98:192:5 56:120:0
INSS stages 1:2:3:4:4s:NA 58:40:47:130:17:3 23:26:31:90:6:0
MYCN status Single:Amplified:NA 232:57:6 133:41:2
Survival time (yrs) #5 (with event):#5 (no event):. 5:NA 73:101:114:7 52:65:59:0
Microarrays with median GNUSE scores.1.0 and with no overall survival time annotation were discarded (NA: not available).
doi:10.1371/journal.pone.0108818.t002
Table 3. Characteristic of patients before/after GNUSE filtering (adenocarcinoma).
Categories Groups Before (n=246) After (n=204)
Age (yrs) Min:Med:Max:NA 30:61:89:66 30:61:76:37
Smoking status Ever:Never:NA 123:123:0 99:105:0
MYC status High:Low:NA 17:207:22 16:187:1
Survival time (yrs) #5 (with event):#5 (no event):. 5:NA 32:93:101:20 27:81:96:0
Microarrays with median GNUSE scores.1.0 and with no overall survival time annotation were discarded (NA: not available).
doi:10.1371/journal.pone.0108818.t003
Robust Selection of Cancer Survival Signatures
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e108818
The features obtained from preprocessing are denoted by
probesets, which correspond to (parts of) exons or genes depending
on microarray platforms. The total numbers of probesets (features)
differ depending on microarray platforms: HG-U133A Plus 2.0
platform contains 54675 probesets (HG-U133A contains about
10000 less probesets), and Human Exon ST v1.0 platform
contains 1432143 probesets, according to the NetAffx probeset
annotation v33.1 from Affymetrix. Each probeset has a summa-
rized expression values of corresponding probes in the original
CEL data, where 9,11 (HG-U133A) or 1,4 (Human Exon ST
v1.0) probes constitute a probeset. For the neuroblastoma data set
(Human Exon ST v1.0), we focused on the core level probesets as
features corresponding to exons that fulfilled three criteria: unique
hybridization, unique localization on one of the human chromo-
somes, and the presence of valid gene assignments. Using the
NetAffx probeset annotation, this resulted in 228476 features.
When prefiltering was applied, the probesets with standard
deviation less than the 99th percentile of the standard deviation
of all features were discarded for each random train set I, resulting
in 2285 features. For adenocarcinoma (HG-U133 Plus 2) and
breast cancer (HG-U133A) data sets, we focused on the grade-A
probesets as features corresponding to genes with unique
hybridization and unique localization. Using the NetAffx anno-
tation, this resulted in 28476 (adenocarcinoma) and 20492 (breast
cancer) features, respectively. When prefiltering was applied, the
probesets with standard deviation less than the 90th percentile of
the standard deviation of all features were discarded for each
random train set I, resulting in 2848 (adenocarcinoma) and 2050
(breast cancer) features.
Clinical covariates were used only for the method Cli, including
the following attributes: age at diagnosis, MYCN status and INSS
stage for neuroblastoma; age, smoking status, gender, stage, and
MYC status for lung adenocarcinoma; age, stage, size of tumor,
and grade for breast cancer.
Robust Signatures
The algorithms RS-PL, RS-L, PL, L, Dev, Cor and Cli were
tested within our evaluation framework (Figure 1: B), using the
Table 4. Characteristic of patients before/after GNUSE filtering (breast cancer).
Categories Groups Before (n=514) After (n=362)
Age (yrs) Min:Med:Max:NA 24:51.53:89.65:159 24:55.45:83.17:150
Grade 1:2:3:NA 81:253:166:14 60:180:112:10
Survival time (yrs) #5 (with event):#5 (no event):. 5:NA 74:15:425:0 54:5:303:0
Microarrays with median GNUSE scores.1.0 and with no overall survival time annotation were discarded (NA: not available).
doi:10.1371/journal.pone.0108818.t004
Table 5. A robust signature obtained with RS-PL from the neuroblastoma data set (p= 0.68).
Gene Mean Frequency # Selected Exons Relevance Rank in Dev Rank in Cor
NTRK1 0.90 3 Neuroblastoma [32] -, -, 112 110, 145, 177
TMEFF2 0.87 1 Neuroblastoma [33,34] - 50
FAM70A 0.85 1 Neuroblastoma [37] - 217
SCN7A 0.83 2 Neuroblastoma [35] -, - 48, 234
AKR1C2 0.82 1 Neuroblastoma [38] - 69
SLC18A2 0.82 1 Brain diseases - 632
CHD5 0.81 4 Neuroblastoma [36] -, -, -, - 12, 30, 76, 87
RGS9 0.81 2 Brain diseases -, - -, 225
ANKFN1 0.80 1 Brain development disorders - 660
LRGUK 0.78 1 Neuroblastoma [39] - 819
POF1B 0.76 1 Brain development disorders [40] - 307
ADRB2 0.75 1 Neuroblastoma [41] - -
AMIGO2 0.74 2 Neuroblastoma [37] -, - -, 1236
PMP22 0.74 1 Neuroblastoma [42] 69 54
ARHGAP36 0.71 1 Neuroblastoma [43] 27 -
HS3ST5 0.70 1 Brain diseases [44] - -
MDGA1 0.70 1 Brain diseases - 74
PGM2L1 0.69 1 Neuroblastoma [45] - 837
EPB41L4A 0.68 1 Other cancers - -
SOX6 0.68 1 Neuroblastoma [46] - 437
The second column shows the mean values of selection probabilities of exon features. Multiple selection of exons from a single gene suggests differential expression,
while the others indicate possible mutations. The relevance of features without references were extracted from the GeneCards (http://www.genecards.org). The
corresponding ranks of chosen features (probesets) in Dev and Cor methods are shown in the last two columns (‘-’ if not chosen).
doi:10.1371/journal.pone.0108818.t005
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same random splits of data across different methods for fair
comparison (see Table S1 for survival time distribution of train
and test sets). This resulted in a sequence of coefficient vectors
b^I1 ,b^I2 , . . . ,b^ITout as an output of each method. These were used to
estimate the selection probability of each feature, P(k). For the
neuroblastoma data set, the baseline probability p was set to the
estimated selection probability of the MYCN amplification status
covariate (p~0:68). For the other two data sets, an arbitrary value
(p~0:85) was defined and robust signatures were obtained.
Table 6. A robust signature obtained with RS-PL from the lung adenocarcinoma data set (p= 0.85).
Gene Frequency Relevance Rank in Dev Rank in Cor
CD302/LY75-CD302 1.0 Lung cancer [47] - 1078
SCN4B 1.0 Lung cancer [48] - -
HLF 0.98 Other cancers - -
FBXO32 0.97 Other cancers [49] - 539
PLAUR 0.97 Lung cancer [50] - 180
COL11A1 0.96 Other cancers 19 -
FAM184A 0.94 Lung adenocarcinoma [51] - -
BUB1B 0.93 Lung cancer [52] - 1018
MCM4 0.93 Lung cancer [53] - 41
CCNB2 0.92 Lung adenocarcinoma [54] - 235
SUSD2 0.92 Lung cancer [55] 56 -
GPR116 0.91 Lung function [56] - -
HJURP 0.90 Lung cancer [57] - -
CYP4B1 0.89 Lung cancer* [58] 21 1038
GFRA1 0.89 Other cancers - 1670
GPR84 0.88 - - 500
LOC100499467 0.88 - - 348
SLC12A8 0.88 - - -
DLGAP5 0.86 Other cancers - -
*It was reported to the contrary that CYP4B1 was normally expressed in lung cancer patients [58]. If the relevance of features was unclear or unknown, it was marked
with hyphens.
doi:10.1371/journal.pone.0108818.t006
Table 7. A robust signature obtained with RS-PL from the breast cancer data set (p= 0.0.85).
Gene Frequency Relevance Rank in Dev Rank in Cor
MELK 0.96 Breast cancer [59] - 58
ZCCHC24 (212419_at) 0.96 Breast Cancer [60] - 17
COL14A1 0.93 Other cancers - 73
ZCCHC24 (212413_at) 0.92 Breast Cancer [60] - 203
CDC20 0.92 Breast cancer [61] - 196
FRZB 0.91 Breast cancer [62] - 1
IGJ 0.91 - 53 32
UBE2C 0.91 Breast cancer [63] - 690
LAMA2 0.90 Breast cancer [64] - 8
SCUBE2 0.90 Breast cancer [65] 28 -
MMP1 0.89 Breast cancer [66] 27 -
FBLN1 0.88 Breast cancer [64,67] - 82
IGH@/IGHA1/IGHA2 0.88 - 47 10
PDGFD 0.87 Breast cancer [68] - 106
RRM2 0.87 Breast cancer [69] - 213
SPARCL1 0.87 Breast cancer [70] - 48
For ZCCHC24, two transcripts (with probeset IDs 212419_at and 212413_at) were chosen.
doi:10.1371/journal.pone.0108818.t007
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Qualitative Validation of Robust Signatures. Tables 5, 6,
and 7 show the features included in robust signatures produced by
RS-PL, for neuroblastoma, lung adenocarcinoma, and breast
cancer, respectively (see Tables S2, S3, and S4 for the
corresponding lists of chosen features and their selection proba-
bility). In each table, selection frequencies of features are shown in
the second column. As for neuroblastoma, data were available
with exon level resolution, so selection frequency values were
averaged over multiple exons if more than one exon was stably
identified for a gene. Selection of multiple exons for a single gene
(Table 5) could imply differential exon usage, which has already
been proven for NTRK1 expression in neuroblastoma: NTRK1
isoforms have been reported to be associated with different patient
outcome [32]. TMEFF2 is a PDGF-AA binding protein associated
with gene silencing [33], while PDGF-AA is known to be
functional in neuroblastoma cell growth [34]. SCN7A and
CHD5 have all been linked causally to neuroblastoma biology
and prognosis [35,36]. The other genes were supported by various
literature (Table 5). Several genes identified by RS-PL were also
supported by literature in lung cancer (Table 6: LY75-CD302,
PLAUR, FAM184A, BUB1B, MBM4, CCNB2, SUSD2, HJURP,
and CYP4B1) and breast cancer (Table 7: MELK, CDC20,
FRZB, UBE2C, LAMA2, SCUBE2, MMP1, FBLN1, PDGFD,
RRM2, and SPARCL1). Taken together, these findings demon-
strate that RS-PL is capable of identifying biologically meaningful
signatures and potentially important biomarkers.
Overall Prediction Performance and Robustness
Figure 2 shows the prediction performance (panels A–C) and
the robustness (panels D–F) of methods over Tout outer
subsampling trials for the three data sets used here (in columns),
in terms of the concordance index for predicting survival risk of
test patients and of the Jaccard index (Eq. (6)), respectively. In this
figure the numbers of selected features were not necessarily the
same, where the numbers would have affected prediction
performance. As a result, the comparison of prediction perfor-
Figure 2. Overall prediction performance and robustness. Prediction performance in the concordance index (panels A, B, and C) and
robustness in the Jaccard index (panels D, E, and F) are shown respectively for neuroblastoma (A/D), lung adenocarcinoma (B/E), and breast cancer (C/
F) data sets. Bands inside of boxes represent median values (A–C). In prediction, the proposed method RS-PL was on a par with Cor but better than
the rest (one-sided paired Welch’s t-test, p,0.001) for neuroblastoma, and the second best for adenocarcinoma and breast cancer. Robustness of RS-
PL was the highest except for Dev.
doi:10.1371/journal.pone.0108818.g002
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mance among different methods may not be completely fair in
Figure 2. Still, it shows the maximal prediction performance when
signatures can be flexible in their size.
Prediction Performance. The prediction performance of
PL and L was improved by the use of our proposed robust
selection (RS) framework (Figure 2: A–C). The improvements
were significant in the following cases: RS-PL. PL for breast
cancer (p,1029); RS-L. L for neuroblastoma (p,10216),
adenocarcinoma (p,0.001), and breast cancer (p,1026). These
results were remarkable since the intent of our RS framework was
to improve robustness, but not necessarily to improve prediction
performance. On the other hand, these results also revealed the
susceptibility of PL and L to overfitting when sample size was
smaller than the number of features.
Comparing the prediction performance of our method RS-PL
to the others, RS-PL was the best performing, or the second best
but consistently well performing across different data sets. For
neuroblastoma, RS-PL performed better in terms of prediction
performance than RS-L (p,0.1) and significantly better than PL
(p,0.001), L, Dev, and Cli (p,1029). There was no significant
difference between RS-PL and Cor. The prediction performance
of RS-PL was the second best in cases of adenocarcinoma and
breast cancer, following Cor and Dev, respectively. However, the
prediction performance of Cor and Dev were inconsistent
considering their ranks of performance over the three data sets:
Cor was ranked at 2nd (neuroblastoma), 1st (adenocarcinoma),
and 4th (breast cancer); Dev was ranked at 5th (neuroblastoma/
adenocarcinoma) and 1st (breast cancer), considering their median
prediction performance. Notably, the performance of Cli was the
worst in every case, supporting the use of high-throughput
genomic data for risk prediction. (For survival probability
predictions of individual patients, see Tables S5, S6, and S7 for
neuroblastoma, lung adenocarcinoma, and breast cancer, respec-
tively.)
Robustness. The robustness of PL and L was improved by
the RS framework (Figure 2: D–F), achieving our main objective:
improvements were about 10,57% (RS-PL vs. PL) and
20,120% (RS-L vs. L), depending on data sets for which the
algorithms were tried.
Overall, RS-PL was the most robust except for Dev. In fact, the
robustness indices of both Dev and Cor were consistently high for
all the three data sets tried. However, the Jaccard index used here
for measuring robustness has several limitations, despite its
capability of comparing feature subsets of different sizes: first,
the Jaccard index is biased since it does not take into account of a
correction for chance selection; second, it completely ignores how
well the ranks of features are preserved amongst different
selections. Therefore, an alternative measure for robustness was
considered subsequently for better evaluation.
Prediction Performance vs. Robustness. Figure 3 posi-
tions the seven algorithms in terms of the two performance
criteria, prediction (median concordance index) and robustness
(Jaccard index), providing a clear view for comparison. Neuro-
blastoma: RS-PL was the best performing considering the two
measures. Dev was more robust than RS-PL, but its prediction
performance was not competent at all. Adenocarcinoma: RS-PL
was still the best except for the two extreme cases, Dev (best
robustness/poor prediction performance) and Cor (best prediction
performance/poor robustness). Breast cancer: Dev was the best
performing method in both criteria, being followed by RS-PL and
RS-L.
Overall, RS-PL outperformed the other multivariate selection
methods (RS-L, PL, and L). The univariate selection methods (Cor
and Dev) were better than RS-PL in certain cases, but their
performance was inconsistent when they were considered on
multiple data sets.
In-Depth Performance Analysis with an Extra Shrinkage
For an accurate comparison of signatures, it is necessary to
produce signatures of the same size from all methods. For this
purpose, we applied an extra shrinkage to all selection algorithms
by choosing the G features with the largest magnitude coefficients
in b^I , so that the same number of features was selected for each
random train index set I. This allows for using the rank-penalized
Kunchvea index (Eq. (7)) instead of the Jaccard index for a more
precise estimation of robustness.
Prediction Performance of Small Signatures. Although
the use of the extra shrinkage here was for making the rank-
Figure 3. Prediction performance vs. robustness. Prediction performance in the median concordance index (x-axis) and robustness in the
Jaccard index (y-axis) are shown respectively for neuroblastoma (panel A), adenocarcinoma (B), and breast cancer (C) data sets. Since no variable
selection is performed for Cli, only its prediction performance is shown as vertical lines.
doi:10.1371/journal.pone.0108818.g003
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penalized Kuncheva index available, it also provided a new
perspective on the prediction performance of models consisting of
small signatures.
In Figure 4: A–C, the prediction performance values in terms of
the median concordance index for signatures of varying sizes G
(denoted by selection sizes) from 1 to 25 are shown (Cli is not
included since it does not perform any variable selection).
Comparing to the median prediction performance without extra
shrinkage (Figure 2: A–C), the results of RS-PL showed that
similar prediction performance values were already achieved by
using only ,20 features in case of neuroblastoma, whereas.25
features were expected to achieve similar prediction performance
for adenocarcinoma and breast cancer data sets.
Robustness of Small Signatures. Figure 4: D–F reports the
robustness of algorithms in terms of the rank-penalized Kuncheva
index, for small signatures of varying sizes up to 25.
In these results, the robustness of Cor was consistently the worst
in the three data sets, although it showed competent robustness in
terms of the Jaccard index previously (Figure 2: D–F). The reason
was that even though similar features were chosen by Cor in
multiple trials, the ranks of features were not preserved. Dev
showed the same issue in case of the adenocarcinoma data set.
These results indicated that despite their high prediction
performance in certain cases, predictors obtained by Cor and
Dev from one data set may not transferable to other data sets: they
may produce poor prediction outcome or different prioritization of
features if applied to other data sets.
Comparing to the previous evaluation of robustness (Figure 2:
D–F), RS-PL was still behind of Dev for the cases of neuroblas-
toma and breast cancer, but it became the most robust for the
adenocarcinoma data set: the reason was that the feature ranks
were well preserved by RS-PL, but not by Dev. Overall, RS-PL
and Dev performed consistently well in terms of robustness
compared to the other methods, but the prediction performance of
Dev was not competent to RS-PL in two cases (neuroblastoma and
adenocarcinoma).
Figure 4. Prediction performance and robustness with an extra shrinkage. Prediction performance in terms of the median concordance
index (panels A, B, and C) and robustness in the rank-penalized Kuncheva index (panels D, E, and F) are shown respectively for neuroblastoma (A/D),
lung adenocarcinoma (B/E), and breast cancer (C/F) data sets. Signatures of different sizes (denoted by selection sizes) were created in the extra
shrinkage step, by choosing the features in b^I with the largest magnitude coefficients. Values are not plotted for the cases where any of Tout trials has
chosen less than a specified selection size before the extra shrinkage.
doi:10.1371/journal.pone.0108818.g004
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Conclusion
Our robust selection (RS) framework successfully improved the
robustness of the popular multivariate signature selection methods,
the lasso (L) and the preconditioned lasso (PL) algorithms, for
predicting survival risk: this was the primary goal of this paper.
The goal was achieved by using an ensemble average of potentially
unstable models obtained with subsamples, where the averaged
model typically had a reduced variance compared to the original
models. Large signatures were obtained by such averaged models,
but shrinking enabled the identification of compact signatures with
negligible effects to prediction performance and robustness (data
not shown).
Prediction performance of L and PL was also improved by our
RS framework, sometimes with high significance, which was an
advantage although it was not necessarily intended. The suggested
algorithm, RS-PL, was the best performing in prediction and
robustness amongst the multivariate signature selection methods
(RS-PL, RS-L, PL, and L). Signatures identified by RS-PL were
well supported by literature, constituting a qualitative validation.
For the comparison of RS-PL (multivariate selection) to Cor and
Dev (popular univariate selection methods in clinical studies),
mixed results were obtained on different data sets. The best
performing methods were: RS-PL for neuroblastoma (in terms of
both prediction and robustness); Cor (in prediction) and RS-PL (in
robustness evaluated with the rank-penalized Kuncheva index) for
lung adenocarcinoma; Dev (in both measures) for breast cancer.
However, as shown in our results, the performance of Cor and
Dev was inconsistent compared to that of RS-PL across multiple
data sets. To the contrary, the performance of RS-PL, which was
the best or the second best to Cor/Dev, was consistent, indicating
that RS-PL can compensate the inconsistency of these univariate
selection methods (in practice, trying all the three methods (RS-
PL, Cor, and Dev) will be recommended for a given data).
Arguments for this aspect leave room for further investigation
however, since our experiments were not explicitly designed for
validating this aspect (especially the selection size of Cor and Dev
were fixed to 100 in our results, which can be adjusted by cross
validation or false-discovery-rate control).
Since our method is based on generalized linear models that are
capable of handling both continuous and discrete features, it can
be applied to the next generation sequencing data and a mixture of
expression and sequencing data in principle. However, it is
worthwhile to note that a large number of candidate features
makes it challenging to discover signatures with statistical power.
For example, according to Meinshausen and Bu¨hlmann [19], only
the top few features will be statistically meaningful in our setting.
The best option will be increasing the number of patients, but it is
typically not plausible in clinical studies. Therefore, it is still an
open question how to properly handle a large number of features
given a small number of patients.
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